Mr. James Howard-Tripp reports

STAGEZERO LIFE SCIENCES, LTD ANNOUNCES RESULTS OF RESOLUTIONS AT ANNUAL AND SPECIAL MEETING

Stagezero Life Sciences Ltd. shareholders voted in favour of all of the tabled resolutions listed in the company's management information circular dated April 28, 2023, at its annual and special meeting of shareholders held on June 7, 2023.

The results of the vote for the election of directors are as shown in the attached table.

Shareholders also voted in favour of the following matters:

• Appointment of SRCO Professional Services LLP as auditor of the company with 96 per cent votes for;
• Approval of an ordinary resolution authorizing and approving matters related to private placement transactions pursuant to the capital commitment agreement dated Nov. 17, 2022, between the corporation and GEM Global Yield LLC SCS with 88 per cent votes for; and
• Approval of an ordinary resolution authorizing and approving the issuance of 10,745,077 common shares of the corporation in connection with the conversion of $562,065 (U.S.) notes with 95 per cent for.

"We have high expectations for the company in 2023. We have an extraordinary board and staff who are dedicated to making this a reality and, on behalf of everyone, I would like to thank them. Thank you too to our shareholders for your continued support, it is much appreciated," said James Howard-Tripp, chairman and chief executive officer, Stagezero Life Sciences.

More specific details of the matters approved at the meeting are set forth in the circular and posted on the SEDAR. Voting results are released in accordance with Toronto Stock Exchange (TSX) requirements.

About Stagezero Life Sciences Ltd.

Stagezero Life Sciences is a vertically integrated health care company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT).

The company's next-generation test, Aristotle, is the first ever mRNA multicancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The care oncology clinic offers a supervised treatment regimen (the COC protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult over all for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.

AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. The company's program includes: a comprehensive on-line health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments; and interval screening.

Aristotle, as well as additional cancer diagnostics (ColonSentry and the Prostate Health Index) are processed at the company's clinical laboratory, Stagezero Life Sciences, a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Va.

Stagezero Life Sciences trades on the Toronto Stock Exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.

We seek Safe Harbor.